Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Mar;41(3):607–610. doi: 10.1128/aac.41.3.607

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

N Lounis 1, B Ji 1, C Truffot-Pernot 1, J Grosset 1
PMCID: PMC163759  PMID: 9056001

Abstract

To identify the most active aminoglycoside or fluoroquinolone for the treatment of tuberculosis, the in vivo activities of four different aminoglycosides and three different fluoroquinolones were compared with that of isoniazid (INH) in a murine tuberculosis model. Mice were each inoculated intravenously with 2.3 x 10(7) CFU of Mycobacterium tuberculosis H37Rv. Treatment began the next day (D1) after inoculation and continued for 4 weeks, at the frequency of six times weekly with one of the following regimens: INH, 25 mg/kg; ofloxacin, 200 mg/kg; levofloxacin, 100 or 200 mg/kg; sparfloxacin (SPFX), 50 mg/kg; and streptomycin, kanamycin, amikacin (AMIKA), and isepamicin, all at 200 mg/kg. The dosages of the treatments were presumably equivalent to their clinically tolerated dosages. The severity of infection and effectiveness of the treatment were assessed by the survival rate, spleen weights, gross lung lesions, and the numbers of CFU in the spleens. The results indicate that INH is more bactericidal than any of the aminoglycosides or fluoroquinolones tested, that AMIKA is the most active aminoglycoside, and that SPFX at 50 mg/kg is far more bactericidal than the treatment with other fluoroquinolones.

Full Text

The Full Text of this article is available as a PDF (81.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen B. W., Mitchison D. A., Chan Y. C., Yew W. W., Allan W. G., Girling D. J. Amikacin in the treatment of pulmonary tuberculosis. Tubercle. 1983 Jun;64(2):111–118. doi: 10.1016/0041-3879(83)90035-1. [DOI] [PubMed] [Google Scholar]
  2. Barr W. H., Colucci R., Radwanski E., Zampaglione N., Cutler D., Lin C. C., Elliott M., Affrime M. B. Pharmacokinetics of isepamicin. J Chemother. 1995 Jun;7 (Suppl 2):53–61. [PubMed] [Google Scholar]
  3. Ben-Dov I., Mason G. R. Drug-resistant tuberculosis in a southern California hospital. Trends from 1969 to 1984. Am Rev Respir Dis. 1987 Jun;135(6):1307–1310. doi: 10.1164/arrd.1987.135.6.1307. [DOI] [PubMed] [Google Scholar]
  4. Blum D. An overview of the safety of isepamicin in adults. J Chemother. 1995 Jun;7 (Suppl 2):87–93. [PubMed] [Google Scholar]
  5. Carbon C. Overview of the efficacy of isepamicin in the adult core clinical trial programme. J Chemother. 1995 Jun;7 (Suppl 2):79–85. [PubMed] [Google Scholar]
  6. Frieden T. R., Sterling T., Pablos-Mendez A., Kilburn J. O., Cauthen G. M., Dooley S. W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993 Feb 25;328(8):521–526. doi: 10.1056/NEJM199302253280801. [DOI] [PubMed] [Google Scholar]
  7. Goble M., Iseman M. D., Madsen L. A., Waite D., Ackerson L., Horsburgh C. R., Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993 Feb 25;328(8):527–532. doi: 10.1056/NEJM199302253280802. [DOI] [PubMed] [Google Scholar]
  8. Godfrey K. Statistics in practice. Comparing the means of several groups. N Engl J Med. 1985 Dec 5;313(23):1450–1456. doi: 10.1056/NEJM198512053132305. [DOI] [PubMed] [Google Scholar]
  9. Grosset J. H. Present status of chemotherapy for tuberculosis. Rev Infect Dis. 1989 Mar-Apr;11 (Suppl 2):S347–S352. doi: 10.1093/clinids/11.supplement_2.s347. [DOI] [PubMed] [Google Scholar]
  10. Grosset J., Truffot C., Fermanian J., Lecoeur H. Activité stérilisante des différents antibiotiques dans la tuberculose expérimentale de la souris. Pathol Biol (Paris) 1982 Jun;30(6):444–448. [PubMed] [Google Scholar]
  11. Grumbach F. Etudes chimiothérapiques sur la tuberculose avancée de la souris. Bibl Tuberc. 1965;21:31–96. [PubMed] [Google Scholar]
  12. Grumbach F. Experimental "in vivo" studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin. Tubercle. 1969 Mar;50(Suppl):12–21. [PubMed] [Google Scholar]
  13. Hirano K., Kazumi Y., Abe C., Mori T., Aoki M., Aoyagi T. Resistance to antituberculosis drugs in Japan. Tuber Lung Dis. 1996 Apr;77(2):130–135. doi: 10.1016/s0962-8479(96)90027-1. [DOI] [PubMed] [Google Scholar]
  14. JI B., Lounis N., Truffot-Pernot C., Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341–1344. doi: 10.1128/aac.39.6.1341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ji B., Perani E. G., Petinom C., N'Deli L., Grosset J. H. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother. 1994 Apr;38(4):662–667. doi: 10.1128/aac.38.4.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ji B., Truffot-Pernot C., Grosset J. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle. 1991 Sep;72(3):181–186. doi: 10.1016/0041-3879(91)90004-c. [DOI] [PubMed] [Google Scholar]
  17. Jones R. N. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. J Chemother. 1995 Jun;7 (Suppl 2):7–16. [PubMed] [Google Scholar]
  18. Lalande V., Truffot-Pernot C., Paccaly-Moulin A., Grosset J., Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 1993 Mar;37(3):407–413. doi: 10.1128/aac.37.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sudre P., ten Dam G., Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ. 1992;70(2):149–159. [PMC free article] [PubMed] [Google Scholar]
  20. Truffot-Pernot C., Ji B., Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle. 1991 Mar;72(1):57–64. doi: 10.1016/0041-3879(91)90025-n. [DOI] [PubMed] [Google Scholar]
  21. Tsukamura M., Nakamura E., Yoshii S., Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis. 1985 Mar;131(3):352–356. doi: 10.1164/arrd.1985.131.3.352. [DOI] [PubMed] [Google Scholar]
  22. Turett G. S., Telzak E. E., Torian L. V., Blum S., Alland D., Weisfuse I., Fazal B. A. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995 Nov;21(5):1238–1244. doi: 10.1093/clinids/21.5.1238. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES